Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphoid 1Bronchiolitis Obliterans Syndrome 1

Interventions

Cyclophosphamide 61Rituximab 60Etoposide 28fludarabine phosphate 23Prednisone 23fludarabine 22Vincristine 19Filgrastim 19Doxorubicin 19ibrutinib 16Peripheral Blood Stem Cell Transplantation 16venetoclax 15Lenalidomide 14Bortezomib 14Carboplatin 13CT-P10 13Gemcitabine 12Vorinostat 11Cytarabine 11pembrolizumab 9Radiotherapy 9Melphalan 9Magnetic Resonance Spectroscopy 9Dexamethasone 9Bendamustine Hydrochloride 9Paclitaxel 8Ifosfamide 8Cyclosporine 8Biopsy 8Tacrolimus 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphoma, Large B-Cell, Diffuse × fenebrutinib × Clear all
NCT01991184 2022-06-21

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Genentech, Inc.

Phase 1 Completed
24 enrolled
LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Lymphoid, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡